Randomized trial of standard dose mBACOD with GM-CSF vs reduced dose mBACOD for systemic HIV-associated lymphoma: ACTG 142 (Meeting abstract). NLM AIDSLINE Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Randomized trial of standard dose mBACOD with GM-CSF vs reduced dose mBACOD for systemic HIV-associated lymphoma: ACTG 142 (Meeting abstract).

Proc Annu Meet Am Assoc Cancer Res; 14:A818 1995. Unique Identifier : AIDSLINE ICDB/95613970
Kaplan L; Straus D; Testa M; Levine AM; NIAID AIDS Clinical Trials Group (ACTG), San Francisco, CA

Abstract: The importance of chemotherapy dose intensity in the treatment of individuals with systemic HIV-associated lymphoma was evaluated in a prospective, randomized, multicenter trial. Between Jan 1991 and Sept 1994, 188 HlV-infected individuals with diffuse large cell (34%), large cell immunoblastic (46%), or small noncleaved (20%) lymphomas were randomized to receive: (1) Group 1: methotrexate (M) 200 mg/m2 d15; bleomycin (B) 4 u/m2 d1; doxorubicin (A) 45 mg/m2 d1; cyclophosphamide (C) 600 mg/m2 d1; vincristine (O) 1.4 mg/m2 d1; dexamethasone (D) 6 mg/m2 d1-5 and GM-CSF 5 ug/kg d 4-13 or (2) Group 2 M 200 mg/m2 d15; B: 4 u/m2 d1; A: 25 mg/m2 d1; C: 300 mg/m2 d1; 0: 1.4 mg/m2 d1; D: 3 mg/m2 d1-5 with GM-CSF as needed. Data are shown in a table. The hazard ratios for death were similar for patients with initial CD4 cells greater than 100/mm3 or less than 100/mm3. We conclude that low dose chemotherapy is associated with reduced toxicity and equivalent survival when compared to standard dose therapy in patients with HIV lymphoma.
Keywords: Acquired Immunodeficiency Syndrome/MORTALITY Bleomycin/ADMINISTRATION & DOSAGE Comparative Study Cyclophosphamide/ADMINISTRATION & DOSAGE CD4 Lymphocyte Count Dexamethasone/ADMINISTRATION & DOSAGE Dose-Response Relationship, Drug Doxorubicin/ADMINISTRATION & DOSAGE Granulocyte-Macrophage Colony-Stimulating Factor/*THERAPEUTIC USE Human Leucovorin/ADMINISTRATION & DOSAGE Lymphoma, AIDS-Related/*DRUG THERAPY/MORTALITY/PATHOLOGY Methotrexate/ADMINISTRATION & DOSAGE Neoplasm Staging Proportional Hazards Models Survival Rate Vincristine/ADMINISTRATION & DOSAGE ABSTRACT CLINICAL TRIAL RANDOMIZED CONTROLLED TRIAL
951230
M95C3212

Copyright © 1995 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .